More Company News

Arecor Therapeutics

Completion of AVA6000 sixth dose escalation and clinical update
19 Sep 2023Read More

Arecor Therapeutics

Positive data from first stage of SCIB1 Phase II SCOPE trial in advanced melanoma
19 Sep 2023Read More

Arecor Therapeutics

Interim H123 results
18 Sep 2023Read More

Arecor Therapeutics

Interim H123 results
14 Sep 2023Read More

Arecor Therapeutics

Presentation of results from the Phase IIIb trial of savolitinib at WCLC 2023
12 Sep 2023Read More

Arecor Therapeutics

Completion of enrollment in tazemetostat China bridging study in r/r FL
12 Sep 2023Read More

Arecor Therapeutics

Appointment of Head of Business Development
07 Sep 2023Read More

Arecor Therapeutics

AT307 positive FDA pre-IND meeting
07 Sep 2023Read More

Arecor Therapeutics

Interim H123 results
07 Sep 2023Read More

Arecor Therapeutics

Launch of Portrait Flex assay
04 Sep 2023Read More

1 2 3 4 … 64
Return to Arecor Therapeutics
© 2019-22 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).